Bizman loses vision after cataract surgery, alleges negligence
Mumbai: A 67-year-old Navi Mumbai-based businessman, Rajendra Hardayal Gupta, has approached the Maharashtra Medical Council (MMC) and Vashi police, alleging that he permanently lost vision in his left eye after ophthalmologists Dr Chandan Pandit and Dr DV Pandit – a father-son duo – performed cataract surgery on both his eyes. The doctors overlooked Gupta's diabetic condition and bypassed key pre-operative safeguards which caused the vision loss, Gupta has alleged. Lab investigation showed Rajendra Hardayal Guptawas suffering from an infection in his left eye caused by Pseudomonas aeruginosa – a virulent bacterium known to cause rapid and permanent vision loss if not treated promptly
The businessman first consulted the doctors in December 2024. Despite disclosing his uncontrolled diabetes, he was pressured to undergo cataract surgery on his right eye, he told Hindustan Times.
'I was worried about the risks. But they kept saying, 'We've done surgeries on diabetics worse than you. Nothing will go wrong',' he said.
The first surgery was performed on December 31, 2024, after Gupta made an advance payment of ₹ 70,000. Although he experienced a poking sensation, constant discomfort, and blurred vision in the right eye after the surgery, the doctors asked him to be patient and said things would improve with time.
The doctors pushed him for a surgery on the left eye, which was performed on March 27, 2025 after he paid an additional ₹ 30,000. Once again, Gupta told the doctors that he was diabetic and his right eye had not healed yet, and asked if it was okay to go ahead. The doctors insisted that everything would normalise after the second surgery.
Two days later, Gupta's left eye went dark.
'I could feel pain and pressure but couldn't see a thing,' he said. 'When I went to the doctor on April 6, he told me an ulcer had formed and referred me to another centre.'
At the centre where he was referred, a specialist said he was suffering from a severe corneal infection and recommended urgent treatment or corneal transplant if vision did not return. Since Gupta could not afford further surgery, his daughter Deepali took him to another doctor who ran some investigations. The reports showed he was suffering from an infection caused by Pseudomonas aeruginosa – a virulent bacterium known to cause rapid and permanent vision loss if not treated promptly.
Pseudomonas aeruginosa infections occur when the bacteria enter the body through breaks in the skin or mucous membranes, especially in people with weakened immune systems or underlying health conditions. Gupta's family contends he got infected due to his diabetic condition, which weakens the body's ability to fight infections, and possible lapses in surgical hygiene, such as using sterile instruments, maintaining aseptic techniques, and disinfecting the operating environment.
'We kept informing the doctor, but he kept switching eye drops without proper follow-up or preventive care,' said Deepali. 'Pseudomonas aeruginosa rapidly damages the eye—if they had acted in time, my father's vision might have been saved.'
Deepali accused Dr Chandan Pandit of not having a medical degree. 'He uses his father's credentials and signs off documents under that name, which is unethical and possibly illegal,' she alleged.
Dr Chandan Pandit said he and his father had fulfilled their duty in good faith and denied all of Gupta's allegations.
'There was no negligence. The first eye developed a corneal ulcer a week later, which can happen to diabetic patients even without surgery,' he said. 'My father, a qualified senior surgeon, operated on him. Other patients operated before and after him had normal recovery.'
The doctor characterised Gupta's infection as 'an unfortunate immune response'. Regarding concerns about his credentials as a doctor, he said, 'Our MMC registration is under renewal. It's a standard procedure every three years. Everything is under process.'
The MMC confirmed receipt of Gupta's complaint and said a preliminary inquiry was underway.
Meanwhile, Gupta awaits justice, unable to perform daily chores or run his business. 'These surgeries have stolen my sight and independence,' he said. 'I only want accountability so that others aren't left in darkness.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Can injections be needle-free, painless? This Pune-based firm has the answer
Live Events Sarvesh Mutha, MD, IntegriMedical states that this N-FIS system does not involve any needle or skin piercing, resulting in no pain or bruising. IntegriMedical's manufacturing facility in Pune. The company is also in talks with pharmaceutical manufacturers to co-package the N-FIS device along with their vaccines while also looking to collaborate with the government for the HPV vaccine. Vaccinating children is always a challenging task, especially when it involves needles, as they can make the process more unpleasant. But when a toddler somewhere in eastern India slept throughout her vaccination, it was a proud and joyful moment for Sarvesh Mutha . The child was vaccinated through a needle-free injection system (N-FIS) developed by Mutha's company, IntegriMedical 'It was like magic,' says the child's parents. 'The little girl is usually scared of needles, but here, she just slept throughout.'And Mutha is overjoyed. 'It is a great feeling to hear such a story,' he phobia is very common among children. 'Recently, a seven-year-old child who was waiting for his vaccine saw the posters of the N-FIS device in our clinic and was adamant about getting it. He was very happy to receive it,' says Avinash Kulkarni, a Delhi-based senior paediatrician (consultant).IntegriMedical currently offers N-FIS devices for children's vaccinations and has tie-ups with leading hospitals, including Cloudnine, KEM Hospital, Motherhood, Apollo Cradle, etc. N-FIS is now available in more than 1,000 hospitals across the country and in Europe as well.'One of the largest paediatric institutes, called Heim Pál National Pediatric Institute in Hungary, has essentially integrated our product and is looking to use it for haematology and oncology patients as well,' says Mutha. 'Apart from that, we are there in Europe, in Croatia, Slovakia, and Poland. Conversations are on with Germany and the Netherlands, etc. We also have a CDSCO (Central Drugs Standard Control Organisation) approval, which is for India,' he has obtained CE (Conformité Européenne) approval, which allows the firm to sell its products in 30 European countries. The company claims that more than 45,000 kids have been vaccinated with the N-FIS device to date, which indicates growing acceptance of who founded IntegriMedical during the pandemic with his former colleague Ankur Naik and associates Scott McFarland, and Mark Timm, possesses a background in the engineering and medical industry. The founders, with a cumulative experience of 90 years in the healthcare space, recognised that both children and adults often felt anxious about injections, leading to extremely stressful situations in clinics and hospitals.'Often, you would see kids running away as soon as they arrive at the doctor's clinic. I have had many colleagues who have not even taken the Covid-19 shot, purely because of the fear of needles, and that kind of further motivated us to build this NFIS device,' says four years of research and development (R&D) and clinical trials, IntegriMedical commercially launched the N-FIS device in May 2024. The IntegriMedical kit comes with the N-FIS device, a loader, 10 disposable cartridges, 2 vial adapters, 2 pre-filled syringe adapters, and an injection testing foam. The cartridges and vial adapters are disposable, while the device and the loader are reusable. The N-FIS device is made up of stainless steel to ensure a good device is a kind of piston that uses a high-pressure jet stream injector technology, which essentially goes through the pores of micro-orifices to administer the drug inside the body. 'You need to first prepare the N-FIS device by inserting it into the loader, which develops the piston in the device (energy has been developed inside). The cartridges are then filled with the medicine from the pre-filled syringes. These cartridges are then put on the NFIS device. The device is placed at a 90-degree angle to the skin, and a safety cap behind the device is pressed using the thumb, which enables the piston to press the drug inside the skin,' explains Mutha.'There is zero prick and only pressure. With that pressure, the pores increase a little bit. There is an extremely small opening in the skin, which is possibly smaller than an individual hair, and so what happens is, with this pressure, it minutely pierces through the skin and settles into the subcutaneous or the intramuscular region. This phenomenon is effective absorption and broad dispersion. Once it goes into the layer, it will form a pool of medicine, and then it will start dispersing into our body where it is needed,' he states that this system does not involve any needle or skin piercing, resulting in no pain or bruising. According to Mutha, nearly 80% of the kids and the adults (for trials) who have taken injections using their product have experienced zero to a bit of mild needle-free technology has been in the market for a while now, Mutha says it was IntegriMedical which brought the system to India with its patented US patent awarded to IntegriMedical for the N-FIS device covers its specific design and mechanism, with a focus on the configuration and operation of its spring-actuated drug delivery system. 'While needle-free technology itself is not new, our patent protects our unique product construction, including the housing, trigger mechanism, and energy storage system, rather than the broad concept of needle-free injection,' says further mentions that there are certain global companies that have developed needle-free injections. However, their applications are limited. For instance, one of them, he says without disclosing the company name, is into dental applications only; another company is working with pharmaceutical companies but has not released any final product, unlike IntegriMedical. Canada-based NuGen Medical Devices has developed a needle-free injection system for insulin uptake for people with diabetes, but it is available in Canada only. US-based PharmaJet's needle-free injections are used for various vaccines, including influenza, polio, and Covid-19. Its products have a global presence in Europe as well as developing countries like Brazil and a result of its increasing acceptance and market potential for this innovation, Serum Institute, the largest vaccine maker in the world, in April 2024 acquired a 20% stake in IntegriMedical to further advance the needle-free injection system technology. 'IntegriMedical's N-FIS represents a significant advancement in drug delivery, and we envision a needle-free solution to deliver vaccines. We believe this could potentially revolutionise the way we administer vaccines, making the process more comfortable for patients and healthcare professionals,' states Adar Poonawalla, CEO, Serum Institute of India, after the the product seems quite promising, Mutha and his team are struggling with awareness issues. He says that doctors are surely curious and want to adopt this technology; however, they also have a lot of questions and concerns around its efficiency and poses another challenge. The N-FIS device comes in the range of Rs 300-400, which is considered premium in India, while a normal syringe used for vaccination costs around Rs 50. However, both Mutha and Kulkarni state that parents are willing to pay a premium for a completely painless injection for their child. According to them, the price will come down over the years with increased from a regulatory perspective, it takes a lot of time for such a product to be accepted, as per experts. However, if IntegriMedical is able to navigate regulatory compliance in other countries the way it manages in India, experts say N-FIS could be used on a larger mentions that other needle-free injectables have been used globally, such as in South Africa, when there was an endemic of meningitis. 'It wasn't the same device as IntegriMedical but some other needle-free device. So mass vaccination can be done with this needle free, without any problem,' he its Universal Immunisation Programme (UIP), the Indian government provides free vaccinations to children under 12 and pregnant women, with a targeted annual reach of around 26.7 million newborns and 29 million pregnant women. Experts say that IntegriMedical's N-FIS can be very beneficial to further expand the programme. However, there is a limitation. IntegriMedical's N-FIS device is capable of administering only 0.5 ml of drugs. While this volume accommodates most vaccines, any dosage over it will require 2-4 times the shot or must be administered with a May, IntegriMedical achieved a significant milestone by officially launching N-FIS in the gynaecology segment, expanding our footprint beyond paediatrics. 'This is just the beginning, says Mutha. Several other specialities, including IVF and diabetic, present strong potential for integration in the future. As more departments recognise the clinical and patient-centric benefits of needle-free vaccinations, we expect a sharp increase in hospital adoption over the next couple of years,' he company is also in talks with pharmaceutical manufacturers to co-package the N-FIS device along with their vaccines while also looking to collaborate with the government for the HPV to MD Mutha, the company is looking at anywhere between 2 and 5 lakh vaccinations this year. 'Today, around 25 million kids are born every year, and even if you consider five vaccinations per kid a year, the number is just huge,' he global market for needle-free injectors, valued at approximately $1.3 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 7.8%, according to Nilaya Varma, Co-founder of management consultancy Primus Partners. He believes that the needle-less injections will dominate the market in the near future, due to a number of factors, such as the increasing incidence of needle-stick injuries and related infections, the rising prevalence of chronic conditions that necessitate frequent injections, a growing need for mass vaccination and home-based care, as well as advancements in jet-based and spring-based delivery systems.'While it is challenging to determine the precise size of the needle-less injection market in India, it is reasonable to conclude that the future looks promising for this segment in both the Indian and global markets,' Varma per market researcher Grand View Research, India's vaccine market, which generated a revenue of $4.3 billion in 2023, is projected to reach $5.3 billion by 2030, growing at a CAGR of 3.3%. Furthermore, the needle-free vaccine market globally could be worth $27 billion by 2028, as per Mutha. No doubt the opportunity is big, but the question remains: will IntegriMedical be able to navigate the challenges and take a bigger share of it?
New Indian Express
2 hours ago
- New Indian Express
How does air pollution affect heart? Sree Chitra to find out with purifiers
THIRUVANANTHAPURAM: Over the next year, 200 heart patients in Kerala will sleep with a drum-sized cylindrical air purifier beside their beds. This is part of a major study being undertaken by the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) to explore the link between indoor air pollution and heart health. The air purifiers -- supplied by the All India Institute of Medical Sciences (AIIMS), New Delhi -- will continuously monitor indoor air quality even as clinicians track each patient's heart condition. The goal: to understand whether cleaner indoor air can reduce complications in people suffering from heart failure. The Kerala-based project is part of a larger multi-centre research initiative involving AIIMS, New Delhi, and the Dayanand Medical College, Ludhiana, in Punjab -- regions known for far worse air quality than Kerala. Funded by the Indian Council of Medical Research (ICMR), the study is significant as cardiovascular disease remains the leading cause of death in India. 'Air pollution is not just a city or traffic issue. Indoor air, where people spend a majority of their time, can be just as hazardous, especially for those with heart failure,' Dr Harikrishnan S, principal investigator and professor of cardiology at SCTIMST, told TNIE. 'This study asks a crucial question: can reducing indoor air pollution improve outcomes for patients with heart failure?' Each home will be equipped with one of two types of purifiers, distributed randomly. One has a basic bacterial filter while the other comes with both bacterial and dust filters. The devices will measure pollutants from environmental sources and household practices such as cooking. 'Patients will return for clinical review every three months, during which doctors will assess changes in their heart function, specifically the heart's pumping efficiency,' Dr Harikrishnan said. A baseline reading from a central monitor installed at SCTIMST will help interpret the data collected by the homebased machines.
News18
4 hours ago
- News18
Who Is Tonmoy Sharma? Indian-Origin Pharma Magnate Held In US For $149 Million Healthcare Fraud
Originally from Guwahati, Assam, Sharma built a high-profile career in psychiatry and mental health research after earning his MBBS from Dibrugarh University in 1987. Indian-origin pharma magnate and internationally recognized psychiatrist, Tonmoy Sharma, was arrested at Los Angeles International Airport on May 29 for his alleged role in a massive $149 million healthcare fraud. Sharma, 61, is the founder and former CEO of the now-defunct Sovereign Health Group, a California-based addiction treatment network that once operated multiple facilities across the United States. Originally from Guwahati, Assam, Sharma built a high-profile career in psychiatry and mental health research after earning his MBBS from Dibrugarh University in 1987. He later moved to the US to establish his medical and entrepreneurial career, gaining recognition for his groundbreaking work in schizophrenia and mental illnesses. He also held medical licenses in both India and the United Kingdom, and contributed to over 200 peer-reviewed journal articles and five books. Sharma was indicted by a federal grand jury on eight criminal counts: four counts of wire fraud, one count of conspiracy, and three counts of illegal remunerations for patient referrals. According to the US Attorney's Office for the Central District of California, his company, Sovereign Health, fraudulently billed more than $149 million to private health insurance companies between 2014 and 2020. The indictment alleges that Sovereign employees, acting under Sharma's direction, used deceptive marketing to lure patients into their facilities. They falsely claimed treatment costs would be covered by a charitable foundation and enrolled patients into insurance plans without their knowledge. The group also billed insurers for unauthorized urinalysis tests, racking up over $29 million in fraudulent claims, and paid over $21 million in illegal kickbacks to secure patient referrals. The investigation into Sovereign Health began in June 2017, leading to FBI raids on the company's treatment centres, its San Clemente headquarters, and Sharma's residence in San Juan Capistrano. The company ultimately shut down operations in 2018. Also arrested was Paul Jin Sen Khor, 45, Sovereign's former cash management and accounts payable supervisor. He has pleaded not guilty, and his trial is scheduled for July 29. Not Just Known For Healthcare Sector Sharma was not only known for his role in the healthcare sector but also for his deep roots in Assam's cultural and intellectual heritage. He is the son of the late Phani Sharma, a prominent theatre personality, filmmaker, and owner of Guwahati's Anuradha Cinema. An expert in brain function, cognition, and behavioral science, Sharma served on multiple editorial boards, peer-reviewed for 15 medical journals, and advised on antipsychotic medications. Despite his respected credentials, his alleged involvement in one of the largest healthcare frauds in US addiction treatment history has sent shockwaves through both the medical and South Asian diaspora communities.
